7^th International Conference and Expo on Molecular & Cancer Biomarkers September 15-16, 2016 Berlin, Germany

Dr. Pant received his M.A. and Ph.D. degrees in Physics from Agra University, Agra, India. His postdoctoral studies were conducted on the mechanisms of electron and ion transport in model membrane systems at the Department of Biophysics at Michigan State University. He joined the Laboratory of Neurobiology in the NIMH as a senior staff fellow in 1974 with Dr. Ichiji Tasaki where he studied the function of the axonal cytoskeleton in the squid giant axon. In 1979 he moved to the NIAAA extending his studies on the neuronal cytoskeleton and the effects of alcohol on its regulation. Dr. Pant moved to the NINDS, Laboratory of Neurochemistry in 1987 where he is presently chief of the section on Cytoskeleton Regulation. His laboratory is studying the mechanisms of topographic regulation of neuronal cytoskeleton proteins by post-translational modification, including the role of kinase cascades in normal brain and during neurodegeneration.

Biomarkers and Neurodegenerative diseases

Shivendra V. Singh earned his M.Sc. and Ph.D. degrees in Biochemistry from the Banaras Hindu University (India). In 1983, Dr. Singh came to the United States to pursue post-doctoral training at the University of Texas Medical Branch, Galveston, TX and studied glutathione-linked detoxification mechanisms. In 1988, Dr. Singh was appointed to the faculty of the University of Miami, School of Medicine as an Assistant Professor in the Department of Medical Oncology. The Mercy Hospital of Pittsburgh recruited Dr. Singh in 1992 to head its Cancer Research Laboratory and direct basic cancer research program. Dr. Singh joined the University of Pittsburgh in 2000 as a Tenured Professor of Pharmacology & Chemical Biology and member of University of Pittsburgh Cancer Institute (UPCI). Dr. Singh holds a secondary appointment in the Department of Urology in School of Medicine, and is the Associate Director for Basic Research at the UPCI. Dr. Singh was honored with UPMC Endowed Chair Cancer Prevention Research in 2014. Dr. Singh is a co-author of over 240 research articles in peer-reviewed journals and 22 review articles/book chapters. Dr. Singh serves on Editorial Boards of various scientific journals, including Cancer Prevention Research, Molecular Cancer Therapeutics, Clinical Cancer Research, Molecular Pharmacology, Molecular Carcinogenesis, Carcinogenesis, and Pharmaceutical Research to name a few. Dr. Singh has served on various grant review panels.

Carcinogenesis, Cancer Therapeutics, Biomarkers

Dr. Luo been studying molecular pathology related to human malignancies in the last 24 years. Currently, he is a Professor of Pathology and Director of High Throughput Genome Center at University of Pittsburgh. In the last 16 years, Dr. Luo has been largely focusing on genetic and molecular mechanism of human prostate and hepatocellular carcinomas. In this period, his group has identified and characterized several genes that are related to prostate cancer and hepatocellular carcinoma, including SAPC, myopodin, CSR1, GPx3, ITGA7, MCM7, MT1h and GPC3. He has characterized several signaling pathways that play critical role in prostate cancer development, including Myopodin-ILK-MCM7 inhibitory signaling, myopodin-zyxin motility inhibition pathway, CSR1-CPSF3, CSR1-SF3A3 and CSR1-XIAP apoptotic pathways, MT1h-EHMT1 egigenomic signaling, ITGA7-HtrA2 tumor suppression pathway, GPx3-PIG3 cell death pathway, AR-MCM7 and MCM7-SF3B3 oncogenic pathways. He proposed prostate cancer field effect in 2002. He is one of the pioneers in utilizing high throughput gene expression and genome analyses to analyze field effects in prostate cancer and liver cancer. He is also the first in using methylation array and whole genome methylation sequencing to analyze prostate cancer. Recently, Dr. Luo’s group found that patterns of copy number variants of certain specific genome loci are predictive of prostate cancer clinical outcomes, regardless tissue origin. His discovery of several novel fusion transcripts and their association with aggressive prostate cancer has brought significant new insight into the field of prostate cancer research. Overall, these findings advance our understanding on how cancer develops and behaves, and lay down the foundation for better future diagnosis and treatment of human malignancies.

Biomarkers, molecular pathology

Dr Scherer obtained his PhD at the Max-Planck-Institute for Immunobiology in Germany. After a postdoctoral position at the UT Southwestern Medical Center in Dallas, USA, until 1999, he has been working on biomarker research and development projects in various positions, in the laboratory, as bioinformatician, and as project manager. Andreas worked for Novartis in Basel, CH, from 2000 until 2007, then as consultant and bioinformatician in his own company in Finland, and as Manager of the Bioinformatics Team at the Australian Genome Research Facility (AGRF) in Melbourne, AU. He is inventor and co-inventor of several biomarker-related gene patents, published a book on microarray data quality, and is involved in international research projects and consortia, such as the US FDA-guided SEQC. Besides his work in his consultancy company “Spheromics”, Andreas is Biomarker Project Director at the Institute for Molecular Medicine Finland (FIMM) at the University of Helsinki, Finland, and has a role as National Coordinator in Finland of the European Research Infrastructure for Translational Medicine, EATRIS, for which he also acts as Co-chair of the Biomarker technology Platform.

Biomarkers, Translational Medicine

Kirti Kaul is currently working as Senior Scientist & Project Manager Scientific Development at Medbiomarkers.

Biomarkers, Molecular Biology

Youhe Gao is a Professor in Beijing Normal University. He received his MD from Peking Union Medical College and his from PhD from University of Connecticut and Postdoctoral training from Beth Israel Deaconess Medical Center, Harvard Medical School. He was the Professor of Department of Pathophysiology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences/ Peking Union Medical College from 2001-2014. His research interests include biomarker discovery in urine, urine biobanking, protein interaction methods and related bioinformatics.

Pathophysiology, Biomarkers, Bioinformatics, Biobanking

Dimitrios H. Roukos is currently working as Founding Director, Centre for Biosystems & Synthetic Genomic Network Medicine - CBS. GenNetMed Ioannina University- Ioannina, Greece. He is also Leader at Translational Research, European Network of Excellence (EUNE) for Gastric Cancer (since 2006) and affiliated to Department of Surgery, Ioannina University Hospital , Ioannina , Greece (since 1990). Dr. D. Roukos has graduated from Athens University School of Medicine, Greece. He underwent specialist training in surgery at the J.W.Goethe-University Hospital in Frankfurt a.M., Germany where received his Doctorate (Dr.med). He moved back to Greece and since 1990 works at the Ioannina University School of Medicine.

Genetics, Pathology, Biomarkers, Systems biology & and cancer networks

Kaushala Prasad Mishra has earned B.Sc and M.Sc. degrees from Allahabad University and Ph.D. from Gujarat University. His areas of Specialization: Life Sciences, Radiation Biology, Biotechnology, Biophysics and chemistry. He has been Research Guide for Ph.D. students in many Universities of India; Successfully guided 41 Ph.D. students and presently guiding 08 students. He has published more than 280 research papers and proceeding papers in National and International Journals. He has delivered more than 300 invited talks in Symposia and Conferences. He is currently the Vice Chancellor of Nehru Gram Bharati University, Allahabad, India. He also served as Head, Radiation Biology and Health Science Division and Senior Scientific Officer of Bhabha Atomic Research Center, Department of Atomic Energy, and Government of India, Chairman, Standing Selection Committee, Member, Trombay Scientific Council, BARC, Member, Health, Safety & Biomedical Group Board, Member, Committee of Atomic Energy Commission on Health and Environment Aspects of Uranium Mining at Jaduguda, Member, Core Expert Group on Chemical Disaster and Nuclear Disaster Management of National Disaster Management Authotrity of India (NDMA). He served as Chancellor's Nominee in Selection Committees of Padmashri Dr. D.Y. Patil Deemed University; Mumbai and West Bengal University of Technology, Kolkata and served as Expert on Selection Committees of IITs and several Universities in India.

Radiation Research, Biomarkers, Biophysics, Biotechnology

Dr. (Prof.) Raisuddin is an academician, academic administrator and active researcher with a track record of over 25 years. He did his doctoral thesis (Ph.D.) work at the Indian Institute of Toxicology Research, IITR (a CSIR national laboratory), Lucknow. Initially, he worked as Scientist at IITR, Lucknow and Bose Institute, Kolkata. In 1994, he joined Jamia Hamdard (Hamdard University), New Delhi as a faculty in the Department of Medical Elementology & Toxicology. He was selected as Commonwealth Fellow in 2002 and worked for about a year at the University of Plymouth, UK as Visiting Scientist in 2003. In 2004, he visited Czech Republic under India National Science Academy (INSA) programme and spent three months as Visiting Scientist at RECETOX (an EU Centre of Excellence), Brno. For two years (2006-08) he was at Hanyang University (among top 5 Korean Universities), Seoul, South Korea as Professor. He has been the Head of the Department of Medical Elementology and Toxicology for three years (March 2012 – May 2015) and is currently Head of the Centre for Translational & Clinical Research. Dr. Raisuddin has been appointed as a member of editorial board of over a dozen international journals.

Biomarkers, Cancer markers, Molecular Biomarkers